The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss
- 1Division of Gastroenterology and Hepatology, Department of Medicine, University Hospital Innsbruck, Innsbruck, Austria
- 2Department of Nuclear Medicine, University Hospital Innsbruck, Innsbruck, Austria
- 3Department of Pathology, University Hospital Innsbruck, Innsbruck, Austria
- Correspondence to:
Dr H Tilg
Department of Medicine, University Hospital Innsbruck, Anichstr 35, 6020 Innsbruck, Austria;
- Accepted 21 September 2004
- Revised 13 September 2004
Background and aims: A substantial proportion of patients with inflammatory bowel disease (IBD) develops osteopenia and osteoporosis in the course of disease. Recent data from a mouse model of colitis suggest that the receptor activator of nuclear factor kappa B (RANKL)/osteoprotegerin (OPG) system may be responsible for bone loss.
Methods: We investigated the activation state of the RANKL/OPG system and its association with bone loss in human IBD. Plasma levels of OPG and RANKL were correlated with bone mineral density and current IBD therapy. Colonic secretion of OPG and RANKL and cell types responsible for such secretion were determined.
Results: OPG plasma levels were elevated 2.4-fold in Crohn’s disease (CD) and 1.9-fold in ulcerative colitis (UC) whereas soluble RANKL (sRANKL) levels were not significantly different in IBD patients compared with healthy controls. High levels of OPG were released from colonic explant cultures (CEC) derived from inflamed IBD specimens, and colonic macrophages and dendritic cells costained for OPG. sRANKL levels from CEC were low both in IBD patients and healthy controls. Interestingly, increased expression of RANKL was mainly confined to cells in the lamina muscularis. A significant negative correlation was found between OPG plasma levels and femoral neck/lumbar spine bone mineral density.
Conclusions: We have demonstrated that IBD is associated with alterations in the RANKL/OPG system. Applying results from a murine model of colitis associated bone loss, the constellation of OPG and sRANKL regulation observed in our study raises the possibility that RANKL/OPG may contribute to the development of bone loss in IBD.
- CD, Crohn’s disease
- UC, ulcerative colitis
- IBD, inflammatory bowel disease
- OPG, osteoprotegerin
- RANKL, receptor activator of nuclear factor kappa B
- sRANKL, soluble receptor activator of nuclear factor kappa B
- BMD, bone mineral density
- mAb, monoclonal antibody
- pAb, polyclonal antibody
- CEC, colonic explant culture
- TNF, tumour necrosis factor
- IL, interleukin
- ELISA, enzyme linked immunosorbent assay
- Crohn’s disease
- ulcerative colitis
- inflammatory bowel disease
- receptor activator of nuclear factor kappa B
- bone mineral density
↵* A R Moschen and A Kaser contributed equally to this work.
Conflict of interest: None declared.